We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Visby Medical

Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, ta... read more Featured Products: More products

Download Mobile App





POC Test Detects and Differentiates Between Upper Respiratory Infections Caused by Influenza and SARS-CoV-2

By LabMedica International staff writers
Posted on 04 Jan 2023
Print article
Image: The Visby Medical portable, instrument-free PCR test delivers results in minutes (Photo courtesy of Visby Medical)
Image: The Visby Medical portable, instrument-free PCR test delivers results in minutes (Photo courtesy of Visby Medical)

A fast, polymerase chain reaction (PCR) device can detect and differentiate between upper respiratory infections caused by Influenza (Flu) A & B, and SARS-CoV-2 (COVID-19).

Visby Medical (San Jose, CA, USA) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Respiratory Health point of care test. Visby Medical has created the first and only "instrument-free" platform that offers true PCR technology; PCR is the gold standard for testing Flu A, Flu B, and COVID-19. The Respiratory Health Test, which fits in the palm of the hand, provides accurate results in under 30 minutes at the point of care, enabling clinicians to accurately diagnose and treat patients.

Both the CDC and the Infectious Disease Society of America recommend clinicians should use rapid molecular assays (i.e., nucleic acid amplification tests) over rapid influenza antigen diagnostic tests (RIDTs) in outpatients to improve detection. However, PCR testing has not been widely adopted in outpatient settings in part, because of the expense required to adopt and maintain PCR instrumentation. The instrument-free Visby Medical device solves this problem. The Visby Medical Respiratory Health Test is the next phase in a robust pipeline that is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

"Accurate, rapid, point of care testing can help physicians prescribe appropriate antiviral medications, minimize viral transmission in waiting rooms, and improve patient satisfaction," said Dr. Gary Schoolnik, Chief Medical Officer at Visby Medical. "Use of the Visby Respiratory Health Test at the point of care in urgent care clinics and emergency rooms will transform how patients with respiratory symptoms are diagnosed and treated."

Related Links:
Visby Medical

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.